$EVH News

JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6

TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6

5 Must-Read Analyst Questions From Evolent Health’s Q2 Earnings Call

Evolent Health (EVH) Q2 2026 Earnings Call Transcript

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6

Citigroup Upgrades Evolent Health (EVH)

Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6

Evolent Health, Inc. 2026 Q2 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6

EVH Q2 2026 Deep Dive: Oncology Suite and AI Automation Drive Growth Amid Membership Headwinds

Evolent Health Q2 Earnings Call Highlights

Evolent Health, Inc. Q2 2026 Earnings Call Summary

Evolent Health Inc (EVH) (Q2 2026) Earnings Call Highlights: Revenue Surges 31% and Guidance ...

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

Evolent Health (NYSE:EVH) Jumps 18% After Q2 Revenue and EPS Smash Estimates

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Evolent Health (NYSE:EVH) Reports Bullish Q2 CY2026, Stock Jumps 18.2%

Evolent Announces Second Quarter 2026 Results

Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est